Literature DB >> 32667183

A Universal CAR-NK Cell Targeting Various Epitopes of HIV-1 gp160.

Rebecca M Lim1, Liang Rong1, Anjie Zhen2, Jianming Xie1,3.   

Abstract

Engineering T cells and natural killer (NK) cells with anti-HIV chimeric antigen receptors (CAR) has emerged as a promising strategy to eradicate HIV-infected cells. However, current anti-HIV CARs are limited by targeting a single epitope of the HIV envelope glycoprotein gp160, which cannot counter the enormous diversity and mutability of viruses. Here, we report the development of a universal CAR-NK cell, which recognizes 2,4-dinitrophenyl (DNP) and can subsequently be redirected to target various epitopes of gp160 using DNP-conjugated antibodies as adaptor molecules. We show that this CAR-NK cell can recognize and kill mimic HIV-infected cell lines expressing subtypes B and C gp160. We additionally find that anti-gp160 antibodies targeting membrane-distal epitopes (including V1/V2, V3, and CD4bs) are more likely to activate universal CAR-NK cells against gp160+ target cells, compared with those targeting membrane-proximal epitopes located in the gp41 MPER. Finally, we confirm that HIV-infected primary human CD4+ T cells can be effectively killed using the same approach. Given that numerous anti-gp160 antibodies with different antigen specificities are readily available, this modular universal CAR-NK cell platform can potentially overcome HIV diversity, thus providing a promising strategy to eradicate HIV-infected cells.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32667183      PMCID: PMC8152219          DOI: 10.1021/acschembio.0c00537

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  70 in total

1.  New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population.

Authors:  Inge Jedema; Nicole M van der Werff; Renée M Y Barge; Roel Willemze; J H Frederik Falkenburg
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

Review 2.  The challenge of HIV-1 subtype diversity.

Authors:  Barbara S Taylor; Magdalena E Sobieszczyk; Francine E McCutchan; Scott M Hammer
Journal:  N Engl J Med       Date:  2008-04-10       Impact factor: 91.245

3.  Ancestral and consensus envelope immunogens for HIV-1 subtype C.

Authors:  Denise L Kothe; Yingying Li; Julie M Decker; Frederic Bibollet-Ruche; Kenneth P Zammit; Maria G Salazar; Yalu Chen; Zhiping Weng; Eric A Weaver; Feng Gao; Barton F Haynes; George M Shaw; Bette T M Korber; Beatrice H Hahn
Journal:  Virology       Date:  2006-06-14       Impact factor: 3.616

4.  Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Ming Li; Feng Gao; John R Mascola; Leonidas Stamatatos; Victoria R Polonis; Marguerite Koutsoukos; Gerald Voss; Paul Goepfert; Peter Gilbert; Kelli M Greene; Miroslawa Bilska; Denise L Kothe; Jesus F Salazar-Gonzalez; Xiping Wei; Julie M Decker; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 5.  Engineering CAR-T cells: Design concepts.

Authors:  Shivani Srivastava; Stanley R Riddell
Journal:  Trends Immunol       Date:  2015-07-11       Impact factor: 16.687

Review 6.  Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease.

Authors:  Patrick J McEnaney; Christopher G Parker; Andrew X Zhang; David A Spiegel
Journal:  ACS Chem Biol       Date:  2012-07-03       Impact factor: 5.100

7.  Treatment of patients with advanced cancer with the natural killer cell line NK-92.

Authors:  Torsten Tonn; Dirk Schwabe; Hans G Klingemann; Sven Becker; Ruth Esser; Ulrike Koehl; Meinolf Suttorp; Erhard Seifried; Oliver G Ottmann; Gesine Bug
Journal:  Cytotherapy       Date:  2013-10-01       Impact factor: 5.414

8.  T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing.

Authors:  Ko Kudo; Chihaya Imai; Paolo Lorenzini; Takahiro Kamiya; Koji Kono; Andrew M Davidoff; Wee Joo Chng; Dario Campana
Journal:  Cancer Res       Date:  2013-11-06       Impact factor: 12.701

Review 9.  The kinetic-segregation model: TCR triggering and beyond.

Authors:  Simon J Davis; P Anton van der Merwe
Journal:  Nat Immunol       Date:  2006-08       Impact factor: 25.606

10.  Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing.

Authors:  Ji Li; Nicola J Stagg; Jennifer Johnston; Michael J Harris; Sam A Menzies; Danielle DiCara; Vanessa Clark; Maria Hristopoulos; Ryan Cook; Dionysos Slaga; Rin Nakamura; Luke McCarty; Siddharth Sukumaran; Elizabeth Luis; Zhengmao Ye; Thomas D Wu; Teiko Sumiyoshi; Dimitry Danilenko; Genee Y Lee; Klara Totpal; Diego Ellerman; Isidro Hötzel; John R James; Teemu T Junttila
Journal:  Cancer Cell       Date:  2017-03-02       Impact factor: 38.585

View more
  9 in total

Review 1.  Antiviral Cell Products against COVID-19: Learning Lessons from Previous Research in Anti-Infective Cell-Based Agents.

Authors:  Irina Chikileva; Irina Shubina; Anzhelika-Mariia Burtseva; Kirill Kirgizov; Nara Stepanyan; Svetlana Varfolomeeva; Mikhail Kiselevskiy
Journal:  Biomedicines       Date:  2022-04-07

Review 2.  Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects.

Authors:  Reza Elahi; Amir Hossein Heidary; Kaveh Hadiloo; Abdolreza Esmaeilzadeh
Journal:  Stem Cell Rev Rep       Date:  2021-09-02       Impact factor: 6.692

Review 3.  Engineered NK Cells Against Cancer and Their Potential Applications Beyond.

Authors:  Maria Karvouni; Marcos Vidal-Manrique; Andreas Lundqvist; Evren Alici
Journal:  Front Immunol       Date:  2022-02-15       Impact factor: 7.561

Review 4.  Targeting NK Cells for HIV-1 Treatment and Reservoir Clearance.

Authors:  Siqin Duan; Shuwen Liu
Journal:  Front Immunol       Date:  2022-03-16       Impact factor: 7.561

Review 5.  Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy.

Authors:  Katharina Eva Ruppel; Stephan Fricke; Ulrike Köhl; Dominik Schmiedel
Journal:  Front Immunol       Date:  2022-03-18       Impact factor: 7.561

6.  Advances in HIV-1-specific chimeric antigen receptor cells to target the HIV-1 reservoir.

Authors:  Madhu C Choudhary; Joshua C Cyktor; Sharon A Riddler
Journal:  J Virus Erad       Date:  2022-06-18

7.  CAR-NK cells from engineered pluripotent stem cells: Off-the-shelf therapeutics for all patients.

Authors:  Shi-Jiang Lu; Qiang Feng
Journal:  Stem Cells Transl Med       Date:  2021-11       Impact factor: 6.940

Review 8.  Negative Regulation and Protective Function of Natural Killer Cells in HIV Infection: Two Sides of a Coin.

Authors:  Yu Sun; Jie Zhou; Yongjun Jiang
Journal:  Front Immunol       Date:  2022-03-07       Impact factor: 7.561

Review 9.  Theranostic cells: emerging clinical applications of synthetic biology.

Authors:  Monica P McNerney; Kailyn E Doiron; Tai L Ng; Timothy Z Chang; Pamela A Silver
Journal:  Nat Rev Genet       Date:  2021-07-07       Impact factor: 53.242

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.